Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04557098
Recruitment Status : Recruiting
First Posted : September 21, 2020
Last Update Posted : January 3, 2022
Information provided by (Responsible Party):
Janssen Research & Development, LLC

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 23, 2023
Estimated Study Completion Date : December 30, 2024